La bourse ferme dans 5 h 36 min

CAC 40
7 131,54
+18,63(+0,26 %)
Euro Stoxx 50
4 196,67
+15,07(+0,36 %)
Dow Jones
32 560,60
+316,02(+0,98 %)
EUR/USD
1,0792
+0,0020(+0,1835 %)
Gold future
1 943,60
+2,50(+0,13 %)
BTC-EUR
26 127,33
+150,21(+0,58 %)

Merck & Co., Inc. (MRK)

NYSE - NYSE Prix différé. Devise en USD

Ajouter à la liste dynamique

105,54

-0,31

(-0,29 %)

À la clôture : 04:03PM EDT

105,87

+0,33

(+0,31 %)

Avant Bourse :

06:09AM EDT

Les cours des transactions proviennent de certains marchés

Cap. boursière	267,586B
Bêta (mensuel sur 5 ans)	0,37
Rapport P/E (sur 12 mois)	38,11
BPA (sur 12 mois)	2,77
Date de bénéfices	27 avr. 2023
Dividende et rendement à terme	2,92 (2,76 %)
Date ex-dividende	14 mars 2023
Objectif sur 1 an	118,04

Tous

ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
ACCESSWIRE
Our Partnerships Help Make Vaccines Accessible Worldwide
Providing vaccines to some of the hardest-to-reach places around the world
ACCESSWIRE
Dedicated To Developing Women Leaders
Merck & Co., Inc.